April 18th 2024
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Expert Commentary on the product profile of Belzutifan for Renal Cell Carcinoma
January 18th 2022In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.
Use of First-Line Post-Protocol Immunotherapy Appears Low in Kidney Cell Carcinoma Clinical Trials
November 22nd 2021In a systemic review assessing the use of first-line post-protocol immunotherapy for patients with kidney cell carcinoma, investigators reported that use was low in randomized clinical trials among patients in the control group.
Adjuvant Pembrolizumab Approved by FDA for Treatment of Renal Cell Carcinoma in Certain Cases
November 18th 2021Patients with intermediate-risk and high-risk renal cell carcinoma had a statistically significant improvement in disease-free survival after being treated with pembrolizumab, which was approved by the FDA.